Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds primary-care doctors often overlook prostate cancer risk in Black men

2.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

5.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot